Intellia Therapeutics Inc (NTLA) financials
Intellia Therapeutics revenue and earnings by year
Intellia Therapeutics's revenue was $67.7 million in the fiscal year to December 31, 2025, up 16.9% from the year before. Net income was -$413 million, -609.9% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 17.0% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 68 | 58 | 36 | 52 | 33 | 58 | 43 | 30 | 26 | 16 |
| Revenue growth | 16.9% | 59.6% | -30.4% | 57.7% | -43.0% | 34.5% | 41.6% | 16.5% | 58.5% | — |
| Operating income | -441 | -534 | -515 | -458 | -268 | -137 | -106 | -91 | -70 | -32 |
| Operating margin | -651.7% | -923.1% | -1420.5% | -879.0% | -810.4% | -235.5% | -246.8% | -298.6% | -266.3% | -195.2% |
| Net income | -413 | -519 | -481 | -474 | -268 | -134 | -100 | -85 | -68 | -32 |
| Net margin | -609.9% | -896.8% | -1326.5% | -909.8% | -810.5% | -231.5% | -230.9% | -280.4% | -258.6% | -192.0% |
| Diluted EPS | -$3.81 | -$5.25 | -$5.42 | -$6.16 | -$3.77 | -$2.41 | -$2.12 | -$1.99 | -$1.88 | — |
| Free cash flow | -396 | -355 | -408 | -347 | -238 | -53 | -110 | -67 | -75 | 30 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open NTLA in Markets.
See also: NTLA returns
No forecast, no recommendation. This page describes Intellia Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.